Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


21.02.24 / Tradegate WKN: A1C017 / Name: Carmat / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Carmat Stock

We can see a decrease in the price for Carmat. Compared to yesterday it has lost -€0.090 (-2.090%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Carmat stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Carmat in the next few years

C******** o* t** e**********
M***** P*******
G***** c******* t* c**********
W********* I********* f** t** n*** y****
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Carmat vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Carmat -2.090% -2.086% -3.429% -58.901% -37.868% - -
Edap Tms S.A. ADR 1.850% -3.571% 0.000% -49.533% 15.880% -32.500% 130.769%
Fonar Corp. New 0.950% 0.000% 20.690% 28.834% 18.644% 32.075% 5.316%
MicroVision Inc -3.320% -12.853% -7.223% -21.390% -22.946% -88.485% 88.932%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-06

Diving into the financials of Carmat, a company within the Healthcare Equipment & Supplies industry, immediately signals an enterprise dealing with significant challenges. The figures suggest a company that hasn't yet reached the profitable phase of its life cycle. It's clear from the outset that Carmat is in a developmental phase, which is quite common for companies within this industry, especially those focused on advanced and innovative healthcare solutions.

The initial impression of Carmat's financials indicates that they are struggling with profitability, as seen by multiple years of negative net incomes. The reported total revenues are significantly low relative to the market capitalization, and the gross profits are in the negative terrain, pointing towards costs outweighing revenues. The balance sheets over the years consistently show a company with more liabilities than assets, indicating potentially precarious financial stability. However, substantial investments in financing activities could signify growth opportunities or significant R&D expenditures which are common in this sector.

In verifying the plausibility and correctness of calculations, the provided ratios and financial statement data indicate consistency in the trends of increasing debt, capital raised through issuance of stock, and the challenging revenue generation which matches a company in a capital-intensive phase of development, which is typical of the Healthcare Equipment & Supplies industry players investing heavily in R&D.


Buy Carmat
Show more

Buy Carmat
Show more

Prediction Buy
Perf. (%) 33.41%
Target price
Ends at 04.11.21

Target price changed to 0.0
Show more